Alendronic Acid
Indication
Osteoporosis (NICE TA464)
NICE TA464 - Bisphosphonates for treating osteoporosis - This guidance partially updates NICE TA 160 -Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women and NICE TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures
Green
Brand:
Nice TA:
464
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) are recommended as options for treating osteoporosis in adults only if:
-
the person is eligible for risk assessment as defined in NICE’s guideline on osteoporosis (recommendations 1.1 and 1.2) and
-
the 10‑year probability of osteoporotic fragility fracture is at least 1%.
Intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating osteoporosis in adults only if:
-
the person is eligible for risk assessment as defined in NICE’s guideline on osteoporosis (recommendations 1.1 and 1.2) and
-
the 10‑year probability of osteoporotic fragility fracture is at least 10% or
-
the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: